The Healthy Brains for Healthy Lives (HBHL) initiative is happy to announce the launch of its Neuro-Innovation Fund. HBHL’s Neuro-Innovation Fund aims to close the gap between proof-of-concept research grants, and funding from traditional investors (angels, venture capitalist, institutional investors). The Fund will provide technology development grants to support further proof of principle and/or add value to new technologies or inventions related to the research themes of HBHL.
2017 Québec Science Discovery of the Year Award goes to the cancer-detection probe developed by Kevin Petrecca and Frédéric Leblond
Québec Science magazine’s 25-year tradition continues: every fall, a jury comprised of researchers and journalists selects the top 10 most impressive discoveries in Quebec in the past year and the public is asked to vote to select the winner. This year, a cancer-detection probe was chosen by nearly a third of approximately 4,400 votes cast in the 2017 Discovery of the Year contest.
Women scientists and clinicians are creators and changemakers, expanding the boundaries of human knowledge
The Neuro has launched Neuro XXceptional - an exciting new year-long video series featuring women who tell us what drove them to become scientists and clinicians, and what they love about their work. At The Neuro, these exceptional professionals are improving the lives of patients, helping us understand how the brain works and how to treat neurological disease.
Healthy Brains for Healthy Lives (HBHL) is a high profile, high priority multidisciplinary and cross-sectoral initiative located at McGill University made possible with support from the Canada First Research Excellence Fund (CFREF). The HBHL Strategic Research Plan outlines the vision, deliverables, and overall goals of the initiative, and the research priorities of its four research themes.
Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
You’re about to turn 60, and you’re fretting. Your mother has had Alzheimer’s disease since the age of 65. At what age will the disease strike you? A Canadian study published in JAMA Neurology shows that the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer’s, the more likely they are to have amyloid plaques, the cause of the cognitive decline associated with the disease, in their brain.
The HCALM Network issues regularly a call for proposals for research projects whose focus is to investigate the relationship between language and access to health care or social services.
Proposals must be e-mailed by Sunday, April 8, 2018.
For all information, click here.
Canada First Research Excellence Fund's investment of $150 million in McGill University's Healthy Brains for Healthy Lives (HBHL) and Western University's BrainsCAN marks a pivotal step that will unlock the mysteries of the human mind and lay the groundwork for a pan-Canadian network of collaboration that promises to uncover new ways to treat, prevent and cure brain disorders.
Volume in brain region linked to physiological changes characteristic of AD
New research has drawn a link between changes in the brain’s anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer’s disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
NeuroSGC created to increase volume and quality of cell assays for drug discovery
A new partnership between the Structural Genomics Consortium (SGC) and the Montreal Neurological Institute and Hospital (The Neuro) will use a unique open science framework to help scientists discover new targets for drug development for neurological diseases.
The partnership, called NeuroSGC, will initially focus on Parkinson’s disease and amyotrophic lateral sclerosis (ALS), two of the most common neurodegenerative diseases.
Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Senate of Canada recognizes outstanding contributions to the community
The Senate of Canada has awarded Alan Evans a Canada 150 medal for his commitment to advancements in Alzheimer’s disease and palliative care research. He was nominated by Senator Judith Seidman, a former research fellow at the Montreal Neurological Institute and Hospital, and Associate Professor of the McGill School of Social Work.
Grants for Heather Durham, Stefano Stifani and Jay Ross total just over $2 million
Three MNI researchers have received grants from the ALS Society of Canada worth a total of more than $2 million.
Brain stimulation can change how much we enjoy and value music
Enjoyment of music is considered a subjective experience; what one person finds gratifying, another may find irritating. Music theorists have long emphasized that although musical taste is relative, our enjoyment of music, be it classical or heavy metal, arises, among other aspects, from structural features of music, such as chord or rhythm patterns that generate anticipation and expectancy.